These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 17335290

  • 1. Inhibition of lipid A biosynthesis as the primary mechanism of CHIR-090 antibiotic activity in Escherichia coli.
    Barb AW, McClerren AL, Snehelatha K, Reynolds CM, Zhou P, Raetz CR.
    Biochemistry; 2007 Mar 27; 46(12):3793-802. PubMed ID: 17335290
    [Abstract] [Full Text] [Related]

  • 2. A slow, tight-binding inhibitor of the zinc-dependent deacetylase LpxC of lipid A biosynthesis with antibiotic activity comparable to ciprofloxacin.
    McClerren AL, Endsley S, Bowman JL, Andersen NH, Guan Z, Rudolph J, Raetz CR.
    Biochemistry; 2005 Dec 20; 44(50):16574-83. PubMed ID: 16342948
    [Abstract] [Full Text] [Related]

  • 3. Antibacterial agents that target lipid A biosynthesis in gram-negative bacteria. Inhibition of diverse UDP-3-O-(r-3-hydroxymyristoyl)-n-acetylglucosamine deacetylases by substrate analogs containing zinc binding motifs.
    Jackman JE, Fierke CA, Tumey LN, Pirrung M, Uchiyama T, Tahir SH, Hindsgaul O, Raetz CR.
    J Biol Chem; 2000 Apr 14; 275(15):11002-9. PubMed ID: 10753902
    [Abstract] [Full Text] [Related]

  • 4. Mechanism and inhibition of LpxC: an essential zinc-dependent deacetylase of bacterial lipid A synthesis.
    Barb AW, Zhou P.
    Curr Pharm Biotechnol; 2008 Feb 14; 9(1):9-15. PubMed ID: 18289052
    [Abstract] [Full Text] [Related]

  • 5. Structure of the metal-dependent deacetylase LpxC from Yersinia enterocolitica complexed with the potent inhibitor CHIR-090 .
    Cole KE, Gattis SG, Angell HD, Fierke CA, Christianson DW.
    Biochemistry; 2011 Jan 18; 50(2):258-65. PubMed ID: 21171638
    [Abstract] [Full Text] [Related]

  • 6. Molecular validation of LpxC as an antibacterial drug target in Pseudomonas aeruginosa.
    Mdluli KE, Witte PR, Kline T, Barb AW, Erwin AL, Mansfield BE, McClerren AL, Pirrung MC, Tumey LN, Warrener P, Raetz CR, Stover CK.
    Antimicrob Agents Chemother; 2006 Jun 18; 50(6):2178-84. PubMed ID: 16723580
    [Abstract] [Full Text] [Related]

  • 7. High susceptibility of MDR and XDR Gram-negative pathogens to biphenyl-diacetylene-based difluoromethyl-allo-threonyl-hydroxamate LpxC inhibitors.
    Titecat M, Liang X, Lee CJ, Charlet A, Hocquet D, Lambert T, Pagès JM, Courcol R, Sebbane F, Toone EJ, Zhou P, Lemaitre N.
    J Antimicrob Chemother; 2016 Oct 18; 71(10):2874-82. PubMed ID: 27330072
    [Abstract] [Full Text] [Related]

  • 8. Design and synthesis of potent Gram-negative specific LpxC inhibitors.
    Mansoor UF, Vitharana D, Reddy PA, Daubaras DL, McNicholas P, Orth P, Black T, Siddiqui MA.
    Bioorg Med Chem Lett; 2011 Feb 15; 21(4):1155-61. PubMed ID: 21273067
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Molecular recognition by Escherichia coli UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase is modulated by bound metal ions.
    Hernick M, Fierke CA.
    Biochemistry; 2006 Dec 12; 45(49):14573-81. PubMed ID: 17144651
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A new class of UDP-3-O-(R-3-hydroxymyristol)-N-acetylglucosamine deacetylase (LpxC) inhibitors for the treatment of Gram-negative infections: PCT application WO 2008027466.
    Cuny GD.
    Expert Opin Ther Pat; 2009 Jun 12; 19(6):893-9. PubMed ID: 19473108
    [Abstract] [Full Text] [Related]

  • 13. Kinetic analysis of the zinc-dependent deacetylase in the lipid A biosynthetic pathway.
    McClerren AL, Zhou P, Guan Z, Raetz CR, Rudolph J.
    Biochemistry; 2005 Feb 01; 44(4):1106-13. PubMed ID: 15667204
    [Abstract] [Full Text] [Related]

  • 14. Structure- and Ligand-Dynamics-Based Design of Novel Antibiotics Targeting Lipid A Enzymes LpxC and LpxH in Gram-Negative Bacteria.
    Zhou P, Hong J.
    Acc Chem Res; 2021 Apr 06; 54(7):1623-1634. PubMed ID: 33720682
    [Abstract] [Full Text] [Related]

  • 15. Structure-based discovery of LpxC inhibitors.
    Zhang J, Chan A, Lippa B, Cross JB, Liu C, Yin N, Romero JA, Lawrence J, Heney R, Herradura P, Goss J, Clark C, Abel C, Zhang Y, Poutsiaka KM, Epie F, Conrad M, Mahamoon A, Nguyen K, Chavan A, Clark E, Li TC, Cheng RK, Wood M, Andersen OA, Brooks M, Kwong J, Barker J, Parr IB, Gu Y, Ryan MD, Coleman S, Metcalf CA.
    Bioorg Med Chem Lett; 2017 Apr 15; 27(8):1670-1680. PubMed ID: 28302397
    [Abstract] [Full Text] [Related]

  • 16. Mechanisms decreasing in vitro susceptibility to the LpxC inhibitor CHIR-090 in the gram-negative pathogen Pseudomonas aeruginosa.
    Caughlan RE, Jones AK, Delucia AM, Woods AL, Xie L, Ma B, Barnes SW, Walker JR, Sprague ER, Yang X, Dean CR.
    Antimicrob Agents Chemother; 2012 Jan 15; 56(1):17-27. PubMed ID: 22024823
    [Abstract] [Full Text] [Related]

  • 17. UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase of Escherichia coli is a zinc metalloenzyme.
    Jackman JE, Raetz CR, Fierke CA.
    Biochemistry; 1999 Feb 09; 38(6):1902-11. PubMed ID: 10026271
    [Abstract] [Full Text] [Related]

  • 18. Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding.
    Barb AW, Jiang L, Raetz CR, Zhou P.
    Proc Natl Acad Sci U S A; 2007 Nov 20; 104(47):18433-8. PubMed ID: 18025458
    [Abstract] [Full Text] [Related]

  • 19. UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) inhibitors: a new class of antibacterial agents.
    Zhang J, Zhang L, Li X, Xu W.
    Curr Med Chem; 2012 Nov 20; 19(13):2038-50. PubMed ID: 22414079
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.